The aim of this report was to assess the added benefit of canagliflozin for the treatment of adult patients with type 2 diabetes mellitus in comparison with the appropriate comparator therapy (ACT) in the following approved subindications:
http://ift.tt/2sen02c
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου